Lexaria Bioscience Corp. (LEXX)

DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know

Lexaria Enters a Material Transfer Agreement With PegBio

Lexaria Enters a Material Transfer Agreement with PegBio

Lexaria Announces Effective Date for Reverse Stock Split

Lexaria Announces Effective Date for Reverse Stock Split

Lexaria Updates Business Development

Lexaria Updates Business Development

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule

GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program